Cellosaurus EW-3 (CVCL_1216)

Cell line name EW-3
Synonyms EW3; IARC-EW3; IARC-EW-3; IARC-EW 3
Accession CVCL_1216
Resource Identification Initiative To cite this cell line use: EW-3 (RRID:CVCL_1216)
Comments Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Disease Ewing sarcoma (NCIt: C4817)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP

Markers:
AmelogeninX,Y
CSF1PO11,12
D13S31712
D16S53911,12
D5S81812
D7S8208,11
TH019.3,10
TPOX8,9
vWA15,16
Publications

PubMed=6713356; DOI=10.1016/0165-4608(84)90002-5
Turc-Carel C., Philip I., Berger M.-P., Philip T., Lenoir G.M.
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12).
Cancer Genet. Cytogenet. 12:1-19(1984)

PubMed=11423975; DOI=10.1038/sj.onc.1204437
Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E., Delattre O.
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.
Oncogene 20:3258-3265(2001)

PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006
Szuhai K., Ijszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.
Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines.
Cancer Genet. Cytogenet. 166:173-179(2006)

PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622
Tirode F., Surdez D., Ma X., Parker M., Le Deley M.C., Bahrami A., Zhang Z., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S., Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O., Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M., Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V., Michon J., Marec-Berard P., Gut I., Downing J., Dyer M., Zhang J., Delattre O.
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Cancer Discov. 4:1342-1353(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line databases/resources Cosmic-CLP; 949161
GDSC; 949161
LINCS_LDP; LCL-1452
Chemistry resources ChEMBL-Cells; CHEMBL3308521
ChEMBL-Targets; CHEMBL2366307
Gene expression databases GEO; GSM510005
GEO; GSM1669789
Polymorphism and mutation databases Cosmic; 684070
Cosmic; 949161
Cosmic; 1995405
Cosmic; 2250460